Clinical Trials Logo

Thermal Burn clinical trials

View clinical trials related to Thermal Burn.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06223269 Recruiting - Wound Heal Clinical Trials

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

Start date: May 9, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.

NCT ID: NCT05084183 Recruiting - Thermal Burn Clinical Trials

Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Start date: February 2, 2022
Phase: N/A
Study type: Interventional

A total of 68 adult and pediatric patients who suffer from at least one discrete partial thickness thermal burn wound (Grade II) will be recruited. Subjects will be randomized (1:1) to either PermeaDerm® or Mepilex Ag®. Evaluations will occur at 7, 14 and 21 days with long term follow-up at 6 and 12 months.

NCT ID: NCT04368117 Recruiting - Burn Injury Clinical Trials

STAT: Standard Therapy Plus Active Therapy

STAT
Start date: October 26, 2020
Phase: N/A
Study type: Interventional

The objective of the study is to assess the efficacy of STAT, an activity-based therapy protocol compared to standard therapy (ST) to improve functional outcome and reduce disability in patients recovering from burn injury. This randomized multi-center trial is designed with two parallel treatment groups: STAT and ST. Efficacy of the STAT protocol will be determined through comparison to the ST only group. It will be conducted at seven burn centers.

NCT ID: NCT04138394 Recruiting - Shock Clinical Trials

VItamin C in Thermal injuRY: The VICToRY Trial

VICToRY
Start date: July 24, 2020
Phase: Phase 3
Study type: Interventional

This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.